
After Biohaven's migraine drug Nurtec ODT was approved for preventative treatment of episodic migraines in addition to its previous approval as an acute treatment, sales have exploded.
On Wednesday, Biohaven announced that Nurtec has brought USD 93m into the company in Q2, which is almost twice as much as analysts had expected. It's also more than twice as much as the quarter before. Biohaven received secondary approval for the drug in late May.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app